Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
5 trials since 2013, 1 ongoing, by the sponsor of the products; see every authorized trial
A phase 2 randomized, double-blind, multicenter study to evaluate the safety and efficacy of oral rilzabrutinib…Jan 27, 2021 · Pending · Rilzabrutinib (PRN1008) / Mycophenolate
A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study with an open-label extension…Dec 1, 2020 · Ongoing · Rilzabrutinib (PRN1008)
An open label, two-arm, phase 2a study to evaluate the effect of rilzabrutinib (PRN1008/SAR444671) on safety and…Apr 8, 2020 · Closed · Rilzabrutinib (PRN1008)
A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of oral btk…Feb 28, 2019 · Closed · Rilzabrutinib (PRN1008) / Rituximab
An adaptive, open-label, dose-finding, phase 1/2 study investigating the safety, pharmacokinetics, and clinical…Feb 21, 2019 · Closed · Rilzabrutinib (PRN1008)
Payments to doctors (Open Payments)
What this company reported paying US doctors and teaching hospitals each year, $2.5M of it for research; see every company
$645K20202020Paid$645K
$1.8M20212021Paid$1.8Mvs 2020+$1.2M
Orphan designations (FDA)
One designation since 1983, 0 approved for the designated use, matched by the sponsor's name; see all orphan designations
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.